Single Session Intervention to Promote Hope

March 25, 2026 updated by: Yale University

Hope as a Path to Healing: Developing a Single-Session Intervention for Women Who Experience Intimate Partner Violence

The purpose of this study is to develop a brief, self-guided single-session intervention (SSI) that targets the development of, or increase in, hope, and pilot test it for the primary outcomes of feasibility, acceptability/likeability, safety, and changes in hope, and the secondary outcomes of self-worth, empowerment, and emotional wellbeing among women experiencing intimate partner violence (IPV). The study will be conducted in 2 stages: intervention development (Intervention Development Stage), and pilot testing the intervention (Pilot Stage). The focus of this registration is the Pilot Stage.

Study Overview

Status

Completed

Conditions

Detailed Description

This study aims to accomplish two primary objectives: Objective 1 (Intervention Development Stage): Develop a brief, self-guided SSI to enhance hope and in turn, self-worth, empowerment, and emotional wellbeing, and Objective 2 (Pilot Stage): Pilot test the intervention and evaluate the process of implementation and primary outcomes of feasibility, acceptability/likability, and safety; and to assess changes in hope and secondary outcomes of self-worth, empowerment, and emotional wellbeing.

The Pilot Stage will utilize micro-longitudinal methods (i.e., daily self-reports of hope, self-worth, empowerment, and emotional wellbeing for 14 days before and after the intervention) to assess changes in these constructs. Eligible participants will take part in a baseline interview with a member of the research team. Baseline measures will be based on participant self-report and used to characterize the sample and collect data on person-level control variables. Beginning the day after the baseline interview, participants will complete a brief daily survey on their smartphone. On day 15, participants will receive a link to the SSI and be asked to complete it that day; immediately following the SSI, participants will be asked to complete the post-intervention survey/process supplement to aid in the process evaluation. After completion of the SSI, survivors will participate in 14 additional days of daily data collection to establish post-intervention outcome measures.

Study Type

Interventional

Enrollment (Actual)

97

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Connecticut
      • New Haven, Connecticut, United States, 06511
        • The Consultation Center at Yale

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Pilot Stage:

  • Self-identify as a woman (cis- or trans-gender woman)
  • Currently in a relationship of at least 3 months duration in which they have experienced physical IPV by a male partner
  • Have a smartphone that is compatible with the MyCap app to be able to participate in daily surveys.

Exclusion Criteria:

Pilot Stage:

  • Have experienced significant psychiatric instability based on self-reported inpatient psychiatric hospitalization in the past 3 months
  • Reports having a conservator of person
  • Not comfortable conversing, reading, or writing in English
  • Participated in a Listening Session in the development phase of this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Single-Session Intervention to Promote Hope
A 30-45 minute self-guided intervention delivered in a web browser.
The SSI focuses on increasing hope among women who experience IPV using facts about the brain and IPV research, stories from survivors, and writing exercises.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility assessed by percent enrolled
Time Frame: up to one month
The percent of women enrolled in the study who complete the SSI and individual SSI components.
up to one month
Feasibility assessed by time to complete
Time Frame: up to one month
How long it took a participant to complete the intervention (in minutes), and if it was done in more than one setting.
up to one month
Feasibility assessed by post-intervention survey/process supplement
Time Frame: up to one month
Feasibility will also be assessed in the post-intervention survey/process supplement by asking women 1) where they completed the program, 2) if they listened to the program's read aloud options, and 3) an open-response question about factors that influenced where and when they completed the program since little is known about factors that participation in an intervention of this nature.
up to one month
Acceptability/likability assessed using the Program Feeback Scale
Time Frame: up to one month
The Program Feedback Scale asks participant to rate seven statements regarding intervention acceptability and feasibility; it also includes open-response items that invite participants to share what they liked and/or would change about the intervention. The seven statements are rated from 0 (Strongly Disagree) to 5 (Strongly Agree). Total scores range from 0 to 36, with higher scores indicating a more positive evaluation.
up to one month
Safety assessed using end of study survey
Time Frame: up to one month
Participants will be asked if completing the intervention caused any problems for them and their partner that made them feel unsafe; participants responding in the affirmative will be asked to elaborate in a follow-up open-response question.
up to one month
Change in Hope assessed using Herth Hope Index
Time Frame: baseline (pre intervention) and up to one month (post intervention)
Change in hope will be assessed with daily data using 5 items from the HHI that measure 3 dimensions of hope: 2 items from the temporality and future/cognitive-temporal subscale, 1 item from the positive readiness and expectancy subscale, and 2 items from the interconnectedness subscale. Items are rated from 0 (Strongly Disagree) to 5 (Strongly Agree) with higher values indicating more hope
baseline (pre intervention) and up to one month (post intervention)
Change in Hope assessed using Trait Hope Scale
Time Frame: baseline (pre intervention) and up to one month (post intervention)
Change in hope will be assessed with daily data using 2 items from the Trait Hope Scale; 1 item from the agency subscale and 1 item from the pathway subscale. Items are rated from 0 (Strongly Disagree) to 5 (Strongly Agree), with higher values indicating more hope
baseline (pre intervention) and up to one month (post intervention)
Change in Hope assessed using Beck Hopelessness Scale (single item)
Time Frame: baseline (pre intervention) and up to one month (post intervention)
Hopelessness will be assessed with daily data using 1 item from the Beck Hopelessness Scale. The item is rated on a scale from 0 'Strongly disagree' to 5 'Strongly agree' with higher values indicating higher levels of hopelessness.
baseline (pre intervention) and up to one month (post intervention)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Self-worth
Time Frame: baseline (pre intervention) and up to one month (post intervention)
Change in self-worth will be assessed with daily data using 1 item from the self-esteem/self-efficacy subscale of the Making Decisions and Empowerment Measure. The item is rated on a scale from 0 (Strongly Disagree) to 5 (Strongly Agree).
baseline (pre intervention) and up to one month (post intervention)
Change in Empowerment assessed using The Personal Progress Scale-Revised (PPS-R)
Time Frame: baseline (pre intervention) and up to one month (post intervention)
Changes in empowerment will be assessed with daily data using 2 items from the Personal Progress Scale-Revised. Items are rated on a scale from 0 (Strongly Disagree) to 5 (Strongly Agree). The two items are summed; Scores range from 0-10 with higher scores indicating higher levels of empowerment
baseline (pre intervention) and up to one month (post intervention)
Change in Emotional wellbeing measured by the Patient Health Questionnaire-2 (PHQ-2)
Time Frame: baseline (pre intervention) and up to one month (post intervention)
Changes in emotional wellbeing will be assessed with daily data using the PHQ-2. The two items are rated on a scale from 0 (Not at all) to 3 (Nearly the entire day) and summed, with scores ranging from 0-6, with higher scores indicating higher prevalence depressive symptoms.
baseline (pre intervention) and up to one month (post intervention)
Change in Emotional wellbeing measured by the State Joy Scale
Time Frame: baseline (pre intervention) and up to one month (post intervention)
Changes in emotional wellbeing will be assessed with daily data using 1 item from the State Joy Scale. The item is rated on a on a scale from 0 (Not at all) to 3 (Nearly the entire day) with higher values indicating higher prevalence of joy.
baseline (pre intervention) and up to one month (post intervention)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Tami Sullivan, PhD, Department of Psychiatry, Yale School of Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 7, 2024

Primary Completion (Actual)

January 15, 2026

Study Completion (Actual)

January 15, 2026

Study Registration Dates

First Submitted

April 16, 2024

First Submitted That Met QC Criteria

April 16, 2024

First Posted (Actual)

April 19, 2024

Study Record Updates

Last Update Posted (Actual)

March 27, 2026

Last Update Submitted That Met QC Criteria

March 25, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2000034173
  • 15JOVW-22-GG-04755-STOP (Other Grant/Funding Number: Office on Violence Against Women (OVW))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified data will be archived 90 days before the end of the project period with the National Archive of Criminal Justice Data (NACJD) at the University of Michigan. Investigators will share data collection instruments and analytic code.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Domestic Violence

Clinical Trials on Single-session intervention (SSI)

Subscribe